- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 15033
Historique des publications depuis 10 ans
|
646
|
758
|
943
|
1061
|
1102
|
1295
|
1266
|
1204
|
1192
|
957
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20230 |
325 |
| The Trustees of the University of Pennsylvania | 4376 |
318 |
| The Board of Trustees of the Leland Stanford Junior University | 6509 |
208 |
| Regeneron Pharmaceuticals, Inc. | 4407 |
187 |
| Memorial Sloan-Kettering Cancer Center | 1974 |
186 |
| Board of Regents, The University of Texas System | 5917 |
169 |
| Immatics Biotechnologies GmbH | 1157 |
152 |
| Novartis AG | 10656 |
142 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2895 |
130 |
| The General Hospital Corporation | 4792 |
92 |
| City of Hope | 1004 |
86 |
| Autolus Limited | 260 |
83 |
| Dana-Farber Cancer Institute, Inc. | 2615 |
83 |
| CRISPR Therapeutics AG | 373 |
78 |
| Alpine Immune Sciences, Inc. | 79 |
74 |
| Baylor College of Medicine | 969 |
74 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3367 |
71 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 981 |
69 |
| Juno Therapeutics, Inc. | 448 |
68 |
| Lentigen Technology, Inc. | 100 |
67 |
| Autres propriétaires | 12371 |